

#### This patient is on pomalidomide.

#### Information for Patients:

- You MUST tell your prescriber immediately if you experience any symptom that causes concern.
- You MUST inform your prescriber immediately if you suspect that you or your female partner is pregnant.

### Prescription Details:

Prescription date:	DD	MM	YYYY
Has the patient received counselling?:	Yes		No 🗌
Childbearing potential assessment:	WCBP / WNCBP / Male		
This patient is receiving pomalidomide  Multiple Myeloma or  Relapsed and Refractory Multiple			of:

# Information for Patients and Healthcare Professionals:

# Pomalidomide is an immunomodulator and is an expected human teratogen therefore:

- Women of childbearing potential must use at least one effective method of contraception and male patients with pregnant partners or partners of childbearing potential not using effective contraception must use condoms (even if man has had a vasectomy).
- Women of childbearing potential must have regular pregnancy tests to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation.
- If a female patient or female partner of a male patient suspects they are pregnant they must contact their doctor immediately.

## Emergency contact information:

Emergency Prescriber Contact:
Telephone number during office hours:
Telephone number after office hours:
or complete information on the side effects of pomalidomide, patients should ead the Package Leaflet and Healthcare professionals should read the Summary of

Date of preparation of text: September 2023 Approved by MHRA: November 2023

Product Characteristics

2204-GB-2300043 Version 8